Alarmin cues and regulated cell death calibrate mucosal immunoglobulin A responses and virologic control after intranasal whole-virion inactivated influenza vaccination

Authors:

Abstract
How tissue damage cues and regulated cell death programs instruct antigen-specific mucosal immunoglobulin A (IgA) after vaccination remains incompletely defined. Using a mouse model of intranasal whole-virion inactivated influenza vaccination, we identify two proximal inputs that shape antibody output and virologic control: epithelial necroptosis-associated interleukin (IL)-33 release and a macrophage death-program switch that unmasks IL-1α. Immunization was accompanied by lung cell death, IL-33 release, and the induction of antigen-specific mucosal IgA. In alveolar macrophages, vaccine uptake required phagocytosis and was associated with lysosomal destabilization and cathepsin B activity, which were linked to IL-1α release under conditions that favored regulated necrotic cell death. Consistent with this, pharmacologic inhibition of caspases shifted the dominant death program in alveolar macrophages and was associated with enhanced B cell activation in the cervical lymph nodes and increased iIgA-producing cell-like populations. At the functional level, caspase inhibition augmented vaccine-elicited protection, including reduced lung viral titers and attenuated pathology after homologous challenge and improved control of a within-subtype drift influenza A virus challenge strain; these enhancements were partly dependent on IL-1α. Together, these data support a model in which alarmin cues and regulated cell death pathways in the lung modulate the magnitude of mucosal IgA responses and contribute to virologic control after intranasal whole-virion inactivated influenza vaccination. Limitations include reliance on pharmacologic pathway modulation and a mouse intranasal whole-virion inactivated influenza vaccine model; thus, mechanistic generalization beyond this context should be made cautiously.
Funding Information
  • Japan Agency for Medical Research and Development (JP223fa627005)
  • Japan Agency for Medical Research and Development (JP223fa727002)
  • Japan Agency for Medical Research and Development (JP223fa627005)
  • Japan Agency for Medical Research and Development (JP19ak0101071)
  • Japan Agency for Medical Research and Development (223fa727001j1501)
  • Japan Society for the Promotion of Science (19K12873)